WP
ABEO icon

WealthPLAN Partners’s Abeona Therapeutics ABEO Stock Holding History

WealthPLAN Partners’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-186
Closed -$23.9K – 182
2017
Q1 		$23.9K Buy
+186
New +$24K 0.08% 169
2016
Q3 		$27.9K Sell
186
-415
-69% -$40.6K 0.01% 419
2016
Q2 		$11K Buy
+601
New +$41.1K ﹤0.01% 1697

Other funds holding ABEO

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

WealthPLAN Partners's ABEO Position: Q2 2017 in Review

WealthPLAN Partners sold out of Abeona Therapeutics (ABEO) in Q2 2017, closing a stake of 186 shares — an estimated $23.9K sold.

WealthPLAN Partners first reported a position in ABEO in Q2 2016 and held it in 3 quarters. The position peaked at $27.9K in Q3 2016. 70 funds tracked by Wall St. Rank hold ABEO as of Q2 2017.

  • WealthPLAN Partners reported no remaining Abeona Therapeutics position as of Q2 2017 after selling out during the quarter.
  • WealthPLAN Partners sold 186 Abeona Therapeutics shares in Q2 2017, an estimated $23.9K.
  • WealthPLAN Partners first reported a position in Abeona Therapeutics in Q2 2016 and held it in 3 quarters.
  • WealthPLAN Partners's Abeona Therapeutics position peaked at $27.9K in Q3 2016.
  • 70 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2017.

Based on WealthPLAN Partners's 13F filing for Q2 2017, filed 11 Aug 2017.